contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


aiforia-releases-a-new-ce-ivd-marked-clinical-ai-solution-for-lymph-node-metastasis-detection

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Watched all those videos from this year about Aiforia, it left a good impression of a confident CEO and a company that is constantly winning customers. Looking at that market, it’s in a really good position, and once the customer growth foundation is built, then one would expect it to make a profit.

It’s hard to say how big a deal it would be. Jukka, I think, said that one is certain and the other might go into next year? Many deals go below the reporting threshold.

I am eagerly awaiting to see if there will be any business announcement via Siemens Healthineers by the end of the year. Jukka Tapaninen said in an interview published on November 12th that he expects 1-2 deals before the end of the year, and as a reasonably large player, one would expect it to be quite a significant piece of news regarding Aiforia. Hopefully, it progresses favorably.

No major changes in November’s ownership listing. SEB’s nominee register also no longer continued sales (-200k October, -400k September). Earlier in the year, in April, based on the figures, approx. 1800k transferred from SEB’s register to Citibank’s register.  Edit: It should also be added that SEB’s sales project may, of course, still be ongoing, or it may have been completed. Presumably, so-called smart money knows the situation with their buying services, but for us ‘bulleros,’ dark trading, alternative trading venues, and the secrets of nominee registers – which stock market gentlemen praise as enhancing market efficiency – leave the situation to speculation. Presumably, however, SEB holds shares for several clients, and even a large client may have wanted to lighten their position for one reason or another.                    Aiforia              Aiforia - Osakkeenomistajat    Aiforia on lääketieteen ohjelmistoyritys, joka tarjoaa patologeille ja tutkijoille kliinisissä, prekliinisissä ja akateemisissa laboratorioissa tehokkaan syväoppivan tekoälyohjelmiston.

(I’ve scrolled through this year’s forum threads and haven’t found an answer, so I dare to ask…) According to analysts (Luiro, Rostedt), Aiforia is expected to conduct share issues in '26 and '27. Is there a reason to conduct annual issues and keep the matter repeatedly on management’s agenda? Trust (or signaling of it) in business development and stock price appreciation between issues → less dilution for existing shareholders? I follow the Norwegian market somewhat, and growth companies there tend to seek more substantial funding at once. A larger single funding round is likely a bigger one-time hit to the share price, but at least it removes the dilution concern from the share price for a longer period. In the same breath, I note that Aiforia seems to favor directed share issues, and the risk of depressing the average price before an expected issue is thus smaller.

NuWays video interview that, like Inderes, follows Aiforia. I haven’t watched it yet.

Jukka’s interview from LinkedIn:                   Choose Paris Region              Aiforia launches its AI hub in Paris Region    Founded in 2013, Aiforia is a pioneering healthtech company transforming medical imaging through artificial intelligence and deep learning. Headquartered in Helsinki, the company has rapidly become a reference in AI-powered image analysis, supporting...

Aiforia Technologies

Aiforia releases a new CE-IVD marked clinical AI solution for lymph node metastasis detectionAiforia Technologies Plc, Press Release, September 5, 2025 at 10:30 a.m. EESTAiforia Technologies...

Aiforia releases a new CE-IVD marked clinical AI solution for lymph node metastasis detectionAiforia Technologies Plc, Press Release, September 5, 2025 at 10:30 a.m. EESTAiforia Technologies launches a new CE-IVD marked clinical AI solution for lymph node metastasis detection. The Aiforia® Lymph Node Metastasis AI model supports the detection and quantification of metastases of breast cancer, melanoma, and colorectal cancer in lymph nodes from whole slide images. It has been developed in collaboration with the University of Bern.Lymph node screening is one of the most labor-intensive steps in cancer staging. A single case may require the pathologist to review a multitude of slides under significant time pressure. Aiforia's AI model speeds up the review by providing tools and features that enable rapid navigation to relevant regions within the slides. This enhances workflow efficiency, saving up to 40% of pathologist’s time.“We are proud to launch again a new CE-IVD marked AI solution compliant with the IVDR, this time in collaboration with the University of Bern. This AI solution assists pathologists in the time-consuming task of identifying metastases and helps ensure none goes undetected. It delivers substantial time savings and improves the consistency in the diagnostic workflow,” says Jukka Tapaninen, CEO of Aiforia.Further inquiries Jukka Tapaninen, CEO, Aiforia Technologies Plc tel. +33 61 041 6686 <a href="https://investors.aiforia.com/">https://investors.aiforia.com/ </a>&nbsp;Certified Adviser UB Corporate Finance Ltd <a href="mailto:ubcf@unitedbankers.fi">ubcf@unitedbankers.fi</a>&nbsp;About Aiforia Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers advanced software solutions that elevate diagnostic capabilities in image analysis, empowering remarkable medical discoveries both today and in the future. With thousands of AI models developed for research use and several diagnostic solutions already deployed, Aiforia is making a significant impact on pathology and healthcare.Founded in 2013, Aiforia is a publicly traded company with a global presence and thousands of users worldwide. Headquartered in Helsinki, Finland, the company also operates subsidiaries in the United States and France and maintains a network of local representatives across Europe and North America. Aiforia’s diverse team includes experienced AI and software developers, pathologists, medical scientists, and a dedicated commercial team. Together, they are transforming pathology through AI, enabling better care for every patient.Find out more at <a href="http://www.aiforia.com">www.aiforia.com</a>